Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like that ratio!
What was the overall "buy" rate?
Who is "iker" and "finding bios" on twitter?
Tweet from punit:
@RamosInvestment thanks! We need to continue to get institutional validation along with the fundamentals driving the valuation.
The way I read today's news as a whole is that their will absolutely be a partnership for the combo Phase 2B trial with a PD-1. Let the bidding begin.
The private placement I believe was hinted at in Dr. Pierce's discussion where he mentioned that they are spending a lot of resources in R&D in Seattle developing new pipelines, not even cancer related but indications in the immune system.
I'm curious to see what Punit says tomorrow but I believe ONCS wants to expand their pipeline a lot more and the private placement will help them do that quicker than if they wait.
On May 26, the stock price was .74. It's now .71. Since then we have incredible data, institutions buying in, imminent partnership(s), potential licencing deals, etc. It's all good.
He had such a hard time answering that question while remaining within the SEC.
No kidding. They truly believe they can by-pass phase 3. FDA meeting soon.
Dr. Pierce could literally sell me a piece of chit and I'd like it. He is a great speaker and presenter.
"We are not just an IL-12 company." I like the sound of that.
I just looked at the slides. Definitely new material. Very interested in what Dr. Pierce says.
Absolutely!!!!!! The negative way of looking at this is that we wanted $1+ right now like little babies. The positive way of looking at this is that institutional investors are will to commit 14 million dollars to an OTC stock because of the POTENTIAL.
I believe this is an amazing statement by BIGTIME investors that they believe in ONCS and its potential to bring high returns to its shareholders. This is the type of investing that INO is trying to achieve with its reverse split to attract institutional investors. Until retail investors who are as flighty as the wind, institutional investors provider a much more stable trading environment because they are going to wait for the product to evolve and the pps to go up. For example, the warrants give 1-2 years ago at .25, .35, etc. were finally exercised when the pps went UP!!! As retail investors, we should not be down, we should be thrilled that that amount of money is being committed to ONCS at this stage of its development.
Also, I totally agree with prior posters that this puts ONCS in a different bargaining position with potential partners. Punit knows, and we should know by now, that ONCS owns a state of the art, game changing technology that everyone Big pharma with an anti-PD-1 needs. Believe it friends. After the data presented at ASCO, Punit knows it. I think he is trying to negotiate a really big partnership deal for phase 2B in the neighborhood of 500 million. I think he is sticking it to these big pharma's to pony up. I love it. Believe me, if he negotiates this kind of deal in the next several weeks, no one is going to be sad.
Finally, the timing is interesting but today they are going to an investor conference to sell there product to new investors. Today's commitment from institutional investors is a great selling point in negotiations with future large investors. I love it.
That does suck. You were almost there with your company.
I'm probably wrong, but it feels like there is going to be some serious buying pretty soon today. It seems like the MM's are walking this down and then BOOM! It almost feels like they are walking it down to then buy a chitload to cover from previous trading. Am I reading this wrong?
Lasers, drbob, other science buffs: have you taken a closer look at the slides from yesterday? I truly believe the beauty if yesterday's presentation was in the details. Did you find anything else that caught your eye?
Please give your thoughts. I was inspired yesterday and I'd like to understand even more.
Couldn't interim be sooner?
Hold on friends!!!
I smell bear raid.
Welcome back pal!'n
I disagree. See the following:
Date Symbol Name Short Volume Long Volume Total Volume Short%
2014-06-02 ONCS Oncosec Medical Inc 1552557 2492307 4044864 38
2014-05-30 ONCS Oncosec Medical Inc 1207309 936796 2144105 56
2014-05-29 ONCS Oncosec Medical Inc 631361 482259 1113620 57
2014-05-28 ONCS Oncosec Medical Inc 338978 235035 574013 59
2014-05-27 ONCS Oncosec Medical Inc 383426 690256 1073682 36
2014-05-23 ONCS Oncosec Medical Inc 340083 477396 817479 42
2014-05-22 ONCS Oncosec Medical Inc 286550 472141 758691 38
2014-05-21 ONCS Oncosec Medical Inc 297222 519850 817072 36
2014-05-20 ONCS Oncosec Medical Inc 143198 200808 344006 42
2014-05-19 ONCS Oncosec Medical Inc 291342 542310 833652 35
2014-05-16 ONCS Oncosec Medical Inc 492679 555980 1048659 47
The shorts pile on to any good news and beat it down but they leave after a day or so and the facts prevail.
I know what you mean. Fear of commitment. :). I'm just saying that you have given the board good perspective. That's all.
So far you have been spot on. This was the first day of big volume. By your prediction, we'd is the day.
That would be PVCT.
Or tommy boy. "He could sell a ketchup Popsicle to a man with white gloves."
Agreed. Also, Dr. Pierce one on one with investors. Watch out. :)
If the Nivolumab/ipilimumab combo can get 79% survival rates after two years in metastatic melanoma, imagine what Nivolumab and Immunopulse could do?
Today's presentation was an example of the "devil is in the details" presentation. The overall data and safety profile that was presented was slightly better than the interim data back in December which was already fantastic data. However, the significance of today's presentation was through their understanding of the "de-cloaking" properties of IL-12 that was obtained through their advance research in Seattle, ONCS presented the case to every BIG pharma that owns an anti-PD-1 that no company, and I mean no one, offers the potential combination results that ONCS can offer to them.
Further, because they better understand IL-12's effect on tumors, they can now make the case for combination trials in EVERY cancer, not just melanoma. I believe the market just doesn't understand this significance yet. The market potential just got a lot larger and most people don't even realize it yet.
The question now is not partnership, it is partnerships.
I've never seen Punit so bold but I truly believe that they now have the intra-tumorial data to back up the following claim:
" We're showing clear combination rationale of DNA Il-12 Immunopulse therapy with anti-PD1. #ASCO $ONCS"--Punit on twitter.
The following video illustrates the next couple of weeks for Punit and his team with BIG Pharma:
High resolution poster available.
Higher res version of today's poster presentation is available at the following link: http://ow.ly/xxhyk $ONCS #ASCO14 @asco
Latest Punit tweet:
"We're showing clear combination rationale of DNA Il-12 Immunopulse therapy with anti-PD1. #ASCO $ONCS"
Love it!!!!
Dr. Bob is the man today!!!!! I feel like I'm there. Thanks so much.
Newest Punit tweet:
"To the best of our knowledge, 1st time intratumoral therapy is showing correlation with local response leading to systemic response. #ASCO14"
Just soaking this up. If I didn't have a client coming in in 5 min, I would be drinking. It's 9:00 am here.
That was awesome.
I think slide 7 could turn out to be the most important yet. It is the tumor environment that big pharma is after. Exciting stuff.
The only thing tgvut and jumpiningjacked didn't factor in was greatness. Look at the scoreboard you clowns. Greatness coming June 2.
This is really fun guys!!!
Oh boy. Yes!!!
Here it goes
Ya. No doubt. Thanks again.
Ya. The more technical detail that oncs can show that links there ability to change a non-pd-1 responding tumor environment to be a pd-1 responding environment the better. After thinking about it more, that was my conclusion of why those slides are there.
It's almost as if pierce went down the list of all the flaws of the pd-1 and said here is your solution. Now prize to the highest bidder.